What pharmacovigilance can do for you! relationship assessment is a better concept 24 Nov 2009 3 Dar es Salaam.

Slides:



Advertisements
Similar presentations
Industry Issues: Dataset Preparation for Time to Event Analysis Davis Gates Schering Plough Research Institute.
Advertisements

The management of adverse drug reactions I Ralph Edwards
Safety Reporting IN Clinical Trials
Deriving Biological Inferences From Epidemiologic Studies.
Study Designs in Epidemiologic
The burden of proof Causality FETP India. Competency to be gained from this lecture Understand and use Doll and Hill causality criteria.
Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Elements of a clinical trial research protocol
Hallauer 06/20011 Outcome evaluation of an universal hepatitis B immunisation programme Johannes F. Hallauer M.D. Health Systems Research Charité, Humboldt.
Reviewing the Literature P9419 Class #4 October 20, 2003.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..
1 Causation in Epidemiological Studies Dr. Birgit Greiner Senior Lecturer.
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
P HARMACOVIGILANCE IN P UBLIC H EALTH P ROGRAMME Dr.Sumedh M.Gaikwad MD,DM Clinical Pharmacology, Director Medical Services, Richter Themis Medicare Ltd.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
Chapter 2 Research in Abnormal Psychology. Slide 2 Research in Abnormal Psychology  Clinical researchers face certain challenges that make their investigations.
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Author Name: Kannika Inpra Presenter Name: Kannika Inpra Authors: Inpra K., Suwankesawong W., Kaewvichit S. Institution: Phrae.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd – 28 th November 2009.
Magnus Wallberg Senior Systems Architect M Sc Engineering Physics Dar Es Salaam November 26 th, 2009 Tools for Pharmacovigilance.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.
27 Nov 2009 Dar es Salaam 1 CEM analyses. 27 Nov Dar es Salaam.
27 Nov 2009Dar es Salaam 1 David Coulter. Summary of content  What is a signal?  Recognising a signal  What can be achieved by you?  Clinical assessment.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.
Good Pharmacovigilance Practices
Signal identification and development I.Ralph Edwards.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
Learning About Drug Use1 An Overview of the Process of Changing Drug Use 1. EXAMINE Measure Existing Practices (Descriptive Quantitative Studies) 2. DIAGNOSE.
Paper Writing and Abstract Writing Prof. Peih-ying Lu School of Medicine Kaohsiung Medical University.
[Name of Presenter] [Details of patient e.g. initials, hospital number etc.] [Date of meeting]
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
11 iv. Create standard data collection materials
Detection & monitoring of ADR
8. Causality assessment:
11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.
Safety Reporting Nichol McBee, MPH, CCRP.
Expedited Adverse Event Reporting Requirements
Impact of State Reporting Laws on Central Line– Associated Bloodstream Infection Rates in U.S. Adult Intensive Care Units Hangsheng Liu, Carolyn T. A.
Prescribing.
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
Expedited Adverse Event Reporting Requirements
*Continue on SAE supplemental page CTT21 A if more space is required
9. Introduction to signal detection
Pharmacovigilance (PV)
Causality assessment Using causality models
Patient details Health number: this may be a national identifier (preferred), hospital, clinic, or program number Name: full name is preferable as an accurate.
11 iii. Define management and supervision roles and responsibilities
Pharmaceutical care plans Ola Ali Nassr
Dr Tim England TICH-2 SAE adjudicator
Adverse Event Analysis
Presentation transcript:

What pharmacovigilance can do for you!

relationship assessment is a better concept 24 Nov Dar es Salaam

Outline  Background  Data requirements  Relationship / causality assessment  TEST 24 Nov Dar es Salaam

I’m not going to say much Background 24 Nov Dar es Salaam

Causality assessment Two questions  How close is the relationship between medicine and event?  relationship  Was the event caused by the medicine?  causality 24 Nov Dar es Salaam

Causality assessment Two approaches  Individual case safety reports (ICSRs)  Single reports of suspected reactions  (spontaneous reporting)  Epidemiological  Large numbers of reports of events  Includes CEM 24 Nov Dar es Salaam

Causality Assessment Two definitions  Adverse reaction: “a response to a medicine which is noxious and unintended, and which occurs at doses normally used in man”  Adverse event: any new clinical experience that occurs after commencing a medicine, not necessarily a response to a medicine, and is recorded without judgement on its causality. 24 Nov Dar es Salaam

Understanding events & reactions Events = reactions + incidents (incidents are those events thought not to be reactions –’non-reactions’) 24 Nov Dar es Salaam

I’ll say a little bit more Data requirements 24 Nov Dar es Salaam

What data are needed?  All medicines near the time of the event  dates  doses  indications  The event description  date of onset  duration to onset  event dictionary term 24 Nov Dar es Salaam

What data are needed?  Results of dechallenge & rechallenge  Outcome of the event  Patient medical history  past diseases of importance eg hepatitis  0ther current diseases (co-morbidities) eg  tuberculosis  diabetes 24 Nov Dar es Salaam

Two more definitions  Dechallenge: the outcome of the event after withdrawal of the medicine  resolved, resolving, resolved with sequelae, not resolved, worse, death, unknown  Rechallenge: following dechallenge and recovery from the event, the medicines are tried again, one at a time, under the same conditions as before and the outcome is recorded  recurrence, no recurrence, unknown, (no rechallenge) 24 Nov Dar es Salaam

Where are the data? (CEM)  Medicine details: follow-up Q Section C  ARV medicines  Other medicines  Event details: follow-up Q Section E  Dechallenge & rechallenge: follow-up Q  dechallenge Section C  rechallenge Section E  Event outcome: follow-up Q Section E  Medical history  Baseline E  Treatment initiation C  Any new diseases  Handbook pages Nov Dar es Salaam

The data elements and more  We use all the information available on the report, and  Our pharmacological knowledge, and  Our knowledge of previous reports received, and  Our search of the WHO database (VigiSearch) and  Our knowledge of any literature reports 24 Nov Dar es Salaam

I’m going to say quite a bit Assessment of relationship and causality 24 Nov Dar es Salaam

Assessment of each event 1  Initially, what we are really doing is assessing the strength of the relationship between the drug and the event  We can seldom say without any doubt that a specific drug caused a specific reaction  We work with imperfect data and our conclusions are those of probability 24 Nov Dar es Salaam

Assessment of each event 2 Relationship assessment is an essential discipline. It ensures:  careful review of report details  standardised assessment  an in-depth understanding of the data  standardised data for later evaluation  the ability to sort reports by quality 24 Nov Dar es Salaam

Relationship categories 1. CERTAIN  Event with plausible time relationship  No other explanation -disease or drugs  Event definitive -specific problem  Positive dechallenge  Response to withdrawal plausible  Key feature: Positive rechallenge 24 Nov Dar es Salaam

Relationship categories 2. PROBABLE  Event with plausible time relationship to drug intake  No other explanation  Response to withdrawal (dechallenge) clinically reasonable  No rechallenge, or result unknown  Key feature: Positive dechallenge 24 Nov Dar es Salaam

Relationship categories 3. POSSIBLE  Event with plausible time relationship to drug intake  Could also be explained by disease or other medicines  Information on drug withdrawal lacking or unclear  Key feature: other explanations for the event are possible 24 Nov Dar es Salaam

Relationship categories 4. UNLIKELY  Event with a duration to onset that makes a relationship improbable  Diseases or other drugs provide plausible explanations  Event does not improve after dechallenge  Key feature: several factors indicate strongly that the event is not a reaction 24 Nov Dar es Salaam

Relationship categories 5. UNCLASSIFIED ( conditional)  An adverse event has occurred, but there is insufficient data for adequate assessment and  Additional data is awaited or under examination  Nature of event makes it impossible to attribute causality (needs epidemiological studies)  Key feature: Can’t assess with the information available 24 Nov Dar es Salaam

Relationship categories 6. UNASSESSABLE (unclassifiable)  A report with an event  Cannot be judged because of insufficient or contradictory information  Report cannot be supplemented or verified  Key feature: Data elements concerning the event are inadequate and will not be available 24 Nov Dar es Salaam

The process of assessment 1 Apply a standard event term  Apply a standard term that fits the clinical details  For ICSRs use a reaction dictionary (WHOART / MedDRA) -VigiFlow  For use with Individual Case Safety Reports (spontaneous reports)  Suspected adverse reaction  For event monitoring use the event dictionary -accessible in CemFlow  For use with a CEM programme (event monitoring)  If a suitable term cannot be found, use free text 24 Nov Dar es Salaam

The process of assessment 2 Establishing the relationship Objective evaluation (ICSRs & CEM)  Dates of use of all medicine(s)  Date of onset of event  Response to dechallenge  Response to rechallenge  Outcome  Disease being treated  Other diseases 24 Nov Dar es Salaam

The process of assessment 3 Establishing causality Subjective evaluation (ICSRs& CEM)  Is a reaction plausible?  Consider  indication for use  background or past disease  pharmacology  prior knowledge of similar reports with the suspect drug or related drugs  Is there a possible mechanism? 24 Nov Dar es Salaam

The process of assessment 4 Establishing causality Epidemiological evaluation (CEM)  All the subjective evaluations above  Compare patients with the event of interest with those without the event  Search for non-random results  age  gender  dose  duration to onset (life table analysis)  Other statistical analyses of the data  Disregard events with a relationship of 4, 5 or 6 24 Nov Dar es Salaam

The process of assessment 5 The end process  Discuss and consult  Establish an opinion on causality  Publish  Be prepared to revise your decision 24 Nov Dar es Salaam

Causality Assessment Two questions  How close is the relationship between medicine and event?  relationship  Was the event caused by the medicine?  [What could have caused the event?]  causality 24 Nov Dar es Salaam

Ha Ha!! TEST 24 Nov Dar es Salaam

What relationship? 1 An event with:  a plausible time to onset  no dechallenge information  other medicines could have caused the event  Relationship = Nov Dar es Salaam

What relationship? 2 An event with:  a plausible time to onset  no other obvious causes of the event  positive dechallenge & rechallenge  Relationship = Nov Dar es Salaam

What relationship? 3 An event with:  a plausible time to onset  no other obvious causes of the event  event resolved on dechallenge  a rechallenge was undertaken, but the result is not known  Relationship = Nov Dar es Salaam

What relationship? 4 An event with:  unknown duration to onset  positive dechallenge  rechallenge not stated  no other obvious cause  Relationship = Nov Dar es Salaam

What relationship? 5 An event with:  a plausible time to onset  no other obvious cause  event outcome ‘death’  cause of death was a known reaction to the medicine  Relationship = Nov Dar es Salaam

What relationship? 6 An event with:  a plausible time to onset  no other obvious causes of the event  a dechallenge was undertaken, but the event did not resolve  Relationship = Nov Dar es Salaam

Check your logic  You should not have causality 1  if there has been no rechallenge, or the outcome of rechallenge is unknown  You should not have causality 2  if there has been no dechallenge or the result of dechallenge is unknown or,  if the outcome is unknown or,  if there are other possible causes  You cannot have an event if it started before the medicine!! The process of assessment 6 The very end process 24 Nov Dar es Salaam

The very, very, end (maybe) 24 Nov Dar es Salaam

Practice 1  Male aged 34  On tenofovir, stavudine, efavirenz from Feb 2003  Events  July 2003 had MI –onset 5 months  dyslipidaemia –onset time unknown  Treatment changed (dechallenge)  Outcome:  recovery after angioplasty  no information on lipids  Relationship = ………………………………………..

Practice 2  Male aged 45  receiving HAART for 6 years  2 regimens including ritonavir & lopinavir  Event:  penile ulcers  onset unknown, but after starting ART  biopsy – herpes? –unresponsive to treatment  Treatment stopped July 2007  Outcome: resolved completely in 1 month  Relationship = ………………………………………..

Practice 3  Pregnant woman age 24  LFTs normal  lamivudine, zidovudine, nelfinavir at 16 w  Event -jaundice leading to liver failure  onset after 13 weeks  outcome: recovered after liver transplant  Post op: efavirenz, emtricitabine, tenofovir  well at 12 months  Relationship = ………………………………………..

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

1 James 24 Nov Dar es Salaam

1. James PATIENT IDENTITY 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

2. while 24 Nov Dar es Salaam

2. while TIME / DATE 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

3. sleeping 24 Nov Dar es Salaam

3. sleeping DISEASE 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

4. Bank (where?) 24 Nov Dar es Salaam

4. bank ADDRESS 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

5. flattened 24 Nov Dar es Salaam

5. flattened ADVERSE REACTION 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

6. Sherman 24 Nov Dar es Salaam

6. Sherman PROPRIETARY NAME 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

7. tank 24 Nov Dar es Salaam

7. tank GENERIC NAME 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

8. soft 24 Nov Dar es Salaam

8. soft PREDISPOSING FACTORS 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

9. large 24 Nov Dar es Salaam

9. large DOSE 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

10. buried 24 Nov Dar es Salaam

10. buried DIRECT OUTCOME 24 Nov Dar es Salaam

Data Requirements for Reports James 1, while 2 sleeping 3 on a bank 4 was flattened 5 by a Sherman 6 tank 7. The ground was soft 8, the tank was large 9 and James was buried 10, free of charge Nov Dar es Salaam

11. free of charge 24 Nov Dar es Salaam

11. free of charge INDIRECT OUTCOME 24 Nov Dar es Salaam